anti-.... cholenergics, n/v,Oxytocin, octreotide Flashcards
MOA for Anticholinergics
Aromatic esters that competitively inhibit the effects of ACh at the muscarinic receptors thereby decreasing PNS activity (prevent c AMP and cGMP effects); used for symptomatic brady, anti-sialagogue, Gi spasms and decreases GI secretions, bronchodilation, pea, systole, promotes AW relaxation by inhibing the M2 and M3 causing bronchial SM relaxation and increase HR by blocking the ACh effects at SA node; use with NMB reversal agent
Atropine PK
40%PB to alpha-1-glycoprotein, Vd=1.6L/KG, onset 1 min, peak 1-2min, Do a 30-60min, e1/2 2 hours, hydrolyzed in the liver to tropine and tropic acid and excreted 18% unchanged in the urine
Atropine Se
sedation bc crosses bbb, increases HR, CO, IOP, arrhythmias, blurry vision, decrease secretions and GI motility, bronchodilation
Atropine class
tertiary amine anticholinergic
Atropine CI
glaucoma, patients that tachycardia would be harmful- such as-CAD, hyperpyrexia pts, mobitz type 2
avoid other sympathomimetics
Atropine Dose
0.01mg/kg for reversal; 0.4-0.6 preop antisialagogue, 0.4-1mg for bradycardia; 1mg q3-5min for systole/PEA
Glycopyrrolate class
synthetic quaternary ammonium anticholinergic
Glycopyrrolate Pk
onset 2-3 min, peak 3-5min, DOA 2-4 hours, e1/2 1hour, liver metabolism and 85% excreted unchanged in the urine, poorly lipid soluble
Glycopyrrolate SE
increase HR, CO, IOP, arrhythmias, H/A, blurry vision, decrease secretions and go motility, bronchodilation, MH, decreases sweating, anaphylactic reaction
Glycopyrrolate CI
MH, neonates, CAD, HTN, CHF, glaucoma, hyperpyrexia pts
Glycopyrrolate dose
reversal 0.01-0.02mg/kg IV
anti-sialagogue and bradycardia 0.1-0.2mg
Scopolamine- class
tertiary amine anticholinergic
used for motion sickness, PONV, sedation, bronchodilation; biliary and ureteral SM relaxation, NOT USED FOR REVERSAL NMB
Scopolamine Pk
lipid soluble, onset 10 min, DOA 2 hours, e1/2 4 hours, may last 3-7 days, metabolized by the liver with <1% excreted unchanged in the urine
Scopolamine SE
increase HR, CO, IOP, OH. sedation, arrhythmias, blurry vision. decreases secretions and GI motility
Scopolamine CI
glaucoma liver disease, GI/GU obstruction
Scopolamine dose
0.3-0.6mg IV q4-6 hours
Metoproclamide/reglan
antiemetic, dopamine receptor antagonist and serotonin receptor agonist
Metoproclamide/reglan MOA
blocks the DA2 receptors in the chemo receptor trigger zone of the medullar preventing N/V; also a pro kinetic increasing gastric motility via serotonin increasing peristalsis and increases ACh at the muscarinic receptors post synaptically
Metoproclamide/reglan PK
onset 1-3 min, DOA 1-2 HR, e1/2 2-4hours, metabolized in the liver and 40% excreted unchanged in the urine
Metoproclamide/reglan SE
increase gastric motility, LES tone, decrease N/V, extrapyramidal SE, abd cramping, sedation, prolactin secretion, dry mouth, good for RSI